The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
10.1186/s40880-017-0182-y
- Author:
Kim Saing YOUNG
1
;
Jeong CHI-YOUNG
;
Song HAA-NA
;
Kim Hyo TAE
;
Kim Jun HONG
;
Lee YOUNG-JOON
;
Hong Chan SOON
Author Information
1. Division of Hematology and Oncology
- Keywords:
Biliary tract cancer;
Adjuvant chemotherapy;
Fluoropyrimidine;
R0 resection;
Prognosis
- From:Chinese Journal of Cancer
2017;36(5):222-230
- CountryChina
- Language:Chinese
-
Abstract:
Background: The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains con-troversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection. Methods: We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection. Results: A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%,P= 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%,P= 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages Ⅱ and Ⅲ BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P= 0.002) and 3-year RFS rate (55.5% vs. 39.1%,P= 0.021) compared with observation. Conclusion: Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages Ⅱ and Ⅲ BTC after R0 resection.
